Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 191 entries
Sorted by: Best Match Show Resources per page
Development and optimization of buspirone oral osmotic pump tablet.

Research in pharmaceutical sciences

Derakhshandeh K, Berenji MG.
PMID: 25657794
Res Pharm Sci. 2014 Jul-Aug;9(4):233-41.

The aim of the current study was to design a porous osmotic pump-based drug delivery system for controlling the release of buspirone from the delivery system. The osmotic pump was successfully developed using symmetric membrane coating. The core of...

Cite
Derakhshandeh K, Berenji MG. Development and optimization of buspirone oral osmotic pump tablet. Res Pharm Sci. 2014;9(4):233-41
Derakhshandeh, K., & Berenji, M. G. (2014). Development and optimization of buspirone oral osmotic pump tablet. Research in pharmaceutical sciences, 9(4), 233-41.
Derakhshandeh, K, and Berenji, M Ghasemnejad. "Development and optimization of buspirone oral osmotic pump tablet." Research in pharmaceutical sciences vol. 9,4 (2014): 233-41.
Derakhshandeh K, Berenji MG. Development and optimization of buspirone oral osmotic pump tablet. Res Pharm Sci. 2014 Jul-Aug;9(4):233-41. PMID: 25657794; PMCID: PMC4314871.
Copy Download .nbib Format: NLM
Buspirone vs. Haloperidol: A Double-Blind Trial for Agitation in a Nursing Home Population With Alzheimer's Disease.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry

Cantillon M, Brunswick R, Molina D, Bahro M.
PMID: 28531086
Am J Geriatr Psychiatry. 1996 Summer;4(3):263-267. doi: 10.1097/00019442-199622430-00011. Epub 2012 Aug 14.

The authors report on a pilot double-blind comparison of buspirone with haloperidol in the treatment of agitation manifested by physical tension and motor activity in Alzheimer's disease (AD). A group of 26 nursing home residents underwent a 10-week comparison...

Cite
Cantillon M, Brunswick R, Molina D, et al. Buspirone vs. Haloperidol: A Double-Blind Trial for Agitation in a Nursing Home Population With Alzheimer's Disease. Am J Geriatr Psychiatry. 2012;4(3):263-267doi: 10.1097/00019442-199622430-00011.
Cantillon, M., Brunswick, R., Molina, D., & Bahro, M. (1996). Buspirone vs. Haloperidol: A Double-Blind Trial for Agitation in a Nursing Home Population With Alzheimer's Disease. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 4(3), 263-267. https://doi.org/10.1097/00019442-199622430-00011
Cantillon, Marc, et al. "Buspirone vs. Haloperidol: A Double-Blind Trial for Agitation in a Nursing Home Population With Alzheimer's Disease." The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry vol. 4,3 (1996): 263-267. doi: https://doi.org/10.1097/00019442-199622430-00011
Cantillon M, Brunswick R, Molina D, Bahro M. Buspirone vs. Haloperidol: A Double-Blind Trial for Agitation in a Nursing Home Population With Alzheimer's Disease. Am J Geriatr Psychiatry. 1996 Summer;4(3):263-267. doi: 10.1097/00019442-199622430-00011. Epub 2012 Aug 14. PMID: 28531086.
Copy Download .nbib Format: NLM
Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities.

CNS drugs

Soyka M.
PMID: 27520754
CNS Drugs. 1997 Apr;7(4):313-27. doi: 10.2165/00023210-199707040-00004.

Most psychotropic drugs, such as antipsychotics, lithium and tricyclic antidepressants, do not improve alcohol (ethanol) abstinence rates, at least in alcohol-dependent patients who do not have a comorbid psychiatric disorder. In recent years, numerous studies have been published that...

Cite
Soyka M. Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities. CNS Drugs. 1997;7(4):313-27doi: 10.2165/00023210-199707040-00004.
Soyka, M. (1997). Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities. CNS drugs, 7(4), 313-27. https://doi.org/10.2165/00023210-199707040-00004
Soyka, M. "Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities." CNS drugs vol. 7,4 (1997): 313-27. doi: https://doi.org/10.2165/00023210-199707040-00004
Soyka M. Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities. CNS Drugs. 1997 Apr;7(4):313-27. doi: 10.2165/00023210-199707040-00004. PMID: 27520754.
Copy Download .nbib Format: NLM
Mixed Anxiety and Depression : Diagnosis and Treatment Options.

CNS drugs

Bakish D, Habib R, Hooper CL.
PMID: 27521010
CNS Drugs. 1998 Apr;9(4):271-80. doi: 10.2165/00023210-199809040-00003.

Symptoms of anxiety and depression often appear together in patients, either as 2 discrete disorders, such as major depressive disorder and panic disorder, or as a combination of symptoms not meeting criteria for specific disorders. The social, economic, occupational...

Cite
Bakish D, Habib R, Hooper CL. Mixed Anxiety and Depression : Diagnosis and Treatment Options. CNS Drugs. 1998;9(4):271-80doi: 10.2165/00023210-199809040-00003.
Bakish, D., Habib, R., & Hooper, C. L. (1998). Mixed Anxiety and Depression : Diagnosis and Treatment Options. CNS drugs, 9(4), 271-80. https://doi.org/10.2165/00023210-199809040-00003
Bakish, D, et al. "Mixed Anxiety and Depression : Diagnosis and Treatment Options." CNS drugs vol. 9,4 (1998): 271-80. doi: https://doi.org/10.2165/00023210-199809040-00003
Bakish D, Habib R, Hooper CL. Mixed Anxiety and Depression : Diagnosis and Treatment Options. CNS Drugs. 1998 Apr;9(4):271-80. doi: 10.2165/00023210-199809040-00003. PMID: 27521010.
Copy Download .nbib Format: NLM
Therapy for Cessation of Smoking.

Medical journal, Armed Forces India

Bhattacharyya D, Rai SP, Neog LS.
PMID: 27408159
Med J Armed Forces India. 2008 Jul;64(3):254-9. doi: 10.1016/S0377-1237(08)80107-4. Epub 2011 Jul 21.

Tobacco dependence is a chronic relapsing medical illness. Unfortunately more than 1.1 billion people worldwide smoke tobacco. Tobacco consumption rate is very high in India. Providing three minutes counseling by physicians doubles the cessation rate as compared to no...

Cite
Bhattacharyya D, Rai SP, Neog LS. Therapy for Cessation of Smoking. Med J Armed Forces India. 2011;64(3):254-9doi: 10.1016/S0377-1237(08)80107-4.
Bhattacharyya, D., Rai, S. P., & Neog, L. S. (2008). Therapy for Cessation of Smoking. Medical journal, Armed Forces India, 64(3), 254-9. https://doi.org/10.1016/S0377-1237(08)80107-4
Bhattacharyya, D, et al. "Therapy for Cessation of Smoking." Medical journal, Armed Forces India vol. 64,3 (2008): 254-9. doi: https://doi.org/10.1016/S0377-1237(08)80107-4
Bhattacharyya D, Rai SP, Neog LS. Therapy for Cessation of Smoking. Med J Armed Forces India. 2008 Jul;64(3):254-9. doi: 10.1016/S0377-1237(08)80107-4. Epub 2011 Jul 21. PMID: 27408159; PMCID: PMC4921594.
Copy Download .nbib Format: NLM
The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats.

Advanced pharmaceutical bulletin

Sharifi H, Mohajjel Nayebia A, Farajnia S.
PMID: 24312782
Adv Pharm Bull. 2012;2(1):127-31. doi: 10.5681/apb.2012.019. Epub 2012 May 15.

PURPOSE: Several evidences show that serotonergic neurons play a role in the regulation of movements executed by the basal ganglia. Recently we have reported that single dose of buspirone improved 6-hydroxydopamine (6-OHDA) and haloperidol-induced catalepsy. This study is aimed...

Cite
Sharifi H, Mohajjel Nayebia A, Farajnia S. The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats. Adv Pharm Bull. 2012;2(1):127-31doi: 10.5681/apb.2012.019.
Sharifi, H., Mohajjel Nayebia, A., & Farajnia, S. (2012). The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats. Advanced pharmaceutical bulletin, 2(1), 127-31. https://doi.org/10.5681/apb.2012.019
Sharifi, Hamdolah, et al. "The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats." Advanced pharmaceutical bulletin vol. 2,1 (2012): 127-31. doi: https://doi.org/10.5681/apb.2012.019
Sharifi H, Mohajjel Nayebia A, Farajnia S. The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats. Adv Pharm Bull. 2012;2(1):127-31. doi: 10.5681/apb.2012.019. Epub 2012 May 15. PMID: 24312782; PMCID: PMC3846020.
Copy Download .nbib Format: NLM
A pilot study of serotonin-1A receptor genotypes and rapid eye movement sleep sensitivity to serotonergic/cholinergic imbalance in humans: a pharmacological model of depression.

Nature and science of sleep

Biard K, Douglass AB, Robillard R, De Koninck J.
PMID: 26719734
Nat Sci Sleep. 2015 Dec 18;8:1-8. doi: 10.2147/NSS.S94549. eCollection 2016.

RATIONALE: The serotonergic and cholinergic systems are jointly involved in regulating sleep but this system is theorized to be disturbed in depressed individuals. We previously reported that cholinergic and serotonergic agents induce sleep changes partially consistent with monoamine models...

Cite
Biard K, Douglass AB, Robillard R, et al. A pilot study of serotonin-1A receptor genotypes and rapid eye movement sleep sensitivity to serotonergic/cholinergic imbalance in humans: a pharmacological model of depression. Nat Sci Sleep. 2015;8:1-8doi: 10.2147/NSS.S94549.
Biard, K., Douglass, A. B., Robillard, R., & De Koninck, J. (2016). A pilot study of serotonin-1A receptor genotypes and rapid eye movement sleep sensitivity to serotonergic/cholinergic imbalance in humans: a pharmacological model of depression. Nature and science of sleep, 81-8. https://doi.org/10.2147/NSS.S94549
Biard, Kathleen, et al. "A pilot study of serotonin-1A receptor genotypes and rapid eye movement sleep sensitivity to serotonergic/cholinergic imbalance in humans: a pharmacological model of depression." Nature and science of sleep vol. 8 (2016): 1-8. doi: https://doi.org/10.2147/NSS.S94549
Biard K, Douglass AB, Robillard R, De Koninck J. A pilot study of serotonin-1A receptor genotypes and rapid eye movement sleep sensitivity to serotonergic/cholinergic imbalance in humans: a pharmacological model of depression. Nat Sci Sleep. 2015 Dec 18;8:1-8. doi: 10.2147/NSS.S94549. eCollection 2016. PMID: 26719734; PMCID: PMC4690650.
Copy Download .nbib Format: NLM
Discriminative stimulus effects of the novel anxiolytic buspirone.

Behavioural pharmacology

Ator NA.
PMID: 11224042
Behav Pharmacol. 1991 Feb;2(1):3-14.

Separate groups of Long-Evans rats were trained to discriminate either 0.56 or 1.0mg/kg buspirone i.p. in a two-lever, drug vs no-drug discrimination procedure. Training took twice as long for the lower versus the higher training-dose group. Generalization tests were...

Cite
Ator NA. Discriminative stimulus effects of the novel anxiolytic buspirone. Behav Pharmacol. 1991;2(1):3-14
Ator, N. A. (1991). Discriminative stimulus effects of the novel anxiolytic buspirone. Behavioural pharmacology, 2(1), 3-14.
Ator, N.A.. "Discriminative stimulus effects of the novel anxiolytic buspirone." Behavioural pharmacology vol. 2,1 (1991): 3-14.
Ator NA. Discriminative stimulus effects of the novel anxiolytic buspirone. Behav Pharmacol. 1991 Feb;2(1):3-14. PMID: 11224042.
Copy Download .nbib Format: NLM
Effects of buspirone on antinociceptive and behaviourial responses to the elevated plus-maze in mice.

Behavioural pharmacology

Lee C, Rodgers RJ.
PMID: 11224091
Behav Pharmacol. 1991 Dec;2(6):491-496.

Brief exposure to an elevated plus-maze (EPM) induces antinociception in male mice, a reaction that is not blocked by opiate receptor manipulations but which is completely inhibited by the benzodiazepine receptor agonist, diazepam. The present study examined the effects...

Cite
Lee C, Rodgers RJ. Effects of buspirone on antinociceptive and behaviourial responses to the elevated plus-maze in mice. Behav Pharmacol. 1991;2(6):491-496
Lee, C., & Rodgers, R. J. (1991). Effects of buspirone on antinociceptive and behaviourial responses to the elevated plus-maze in mice. Behavioural pharmacology, 2(6), 491-496.
Lee, C., and Rodgers, R.J.. "Effects of buspirone on antinociceptive and behaviourial responses to the elevated plus-maze in mice." Behavioural pharmacology vol. 2,6 (1991): 491-496.
Lee C, Rodgers RJ. Effects of buspirone on antinociceptive and behaviourial responses to the elevated plus-maze in mice. Behav Pharmacol. 1991 Dec;2(6):491-496. PMID: 11224091.
Copy Download .nbib Format: NLM
Buspirone and lorazepam abuse liability in humans: behavioral effects, subjective effects and choice.

Behavioural pharmacology

Troisi 2nd JR, Critchfield TS, Griffiths RR.
PMID: 11224189
Behav Pharmacol. 1993 Jun;4(3):217-230.

This study compared behavioral and subjective effects of two anxiolytics, the benzodiazepine lorazepam and the azaspirodecanedione buspirone, in healthy male volunteers with histories of sedative drug abuse. Placebo, lorazepam (1, 2, 4, 8mg/70kg) and buspirone (15, 30, 60, 120mg/70kg)...

Cite
Troisi 2nd JR, Critchfield TS, Griffiths RR. Buspirone and lorazepam abuse liability in humans: behavioral effects, subjective effects and choice. Behav Pharmacol. 1993;4(3):217-230
Troisi 2nd, J. R., Critchfield, T. S., & Griffiths, R. R. (1993). Buspirone and lorazepam abuse liability in humans: behavioral effects, subjective effects and choice. Behavioural pharmacology, 4(3), 217-230.
Troisi 2nd, J.R., et al. "Buspirone and lorazepam abuse liability in humans: behavioral effects, subjective effects and choice." Behavioural pharmacology vol. 4,3 (1993): 217-230.
Troisi 2nd JR, Critchfield TS, Griffiths RR. Buspirone and lorazepam abuse liability in humans: behavioral effects, subjective effects and choice. Behav Pharmacol. 1993 Jun;4(3):217-230. PMID: 11224189.
Copy Download .nbib Format: NLM
Pharmacological specificity of the caffeine discriminative stimulus in humans: effects of theophylline, methylphenidate and buspirone.

Behavioural pharmacology

Oliveto AH, Bickel WK, Hughes JR, Terry SY, Higgins ST, Badger GJ.
PMID: 11224191
Behav Pharmacol. 1993 Jun;4(3):237-246.

The present study examined further the pharmacological specificity of the methylxanthine CNS stimulant caffeine as a discriminative stimulus in humans. Nine normal healthy volunteers (ages 19-39) were trained to discriminate between caffeine (320mg/70kg, p.o.) and placebo, using monetary reinforcement...

Cite
Oliveto AH, Bickel WK, Hughes JR, et al. Pharmacological specificity of the caffeine discriminative stimulus in humans: effects of theophylline, methylphenidate and buspirone. Behav Pharmacol. 1993;4(3):237-246
Oliveto, A. H., Bickel, W. K., Hughes, J. R., Terry, S. Y., Higgins, S. T., & Badger, G. J. (1993). Pharmacological specificity of the caffeine discriminative stimulus in humans: effects of theophylline, methylphenidate and buspirone. Behavioural pharmacology, 4(3), 237-246.
Oliveto, A.H., et al. "Pharmacological specificity of the caffeine discriminative stimulus in humans: effects of theophylline, methylphenidate and buspirone." Behavioural pharmacology vol. 4,3 (1993): 237-246.
Oliveto AH, Bickel WK, Hughes JR, Terry SY, Higgins ST, Badger GJ. Pharmacological specificity of the caffeine discriminative stimulus in humans: effects of theophylline, methylphenidate and buspirone. Behav Pharmacol. 1993 Jun;4(3):237-246. PMID: 11224191.
Copy Download .nbib Format: NLM
Noradrenaline-serotonin interactions in the anxiolytic effects of 5-HT(1A) agonists.

Behavioural pharmacology

López-Rubalcava C, Fernández-Guasti A.
PMID: 11224250
Behav Pharmacol. 1994 Feb;5(1):42-51. doi: 10.1097/00008877-199402000-00005.

The purpose of this study was to analyse adrenergic and serotonergic interactions in the anxiolytic effects of several 5-HT(1A) agonists including ipsapirone, buspirone, indorenate and 8-OH-DPAT. To this end, the effects of different doses of the adrenergic compounds clonidine...

Cite
López-Rubalcava C, Fernández-Guasti A. Noradrenaline-serotonin interactions in the anxiolytic effects of 5-HT(1A) agonists. Behav Pharmacol. 1994;5(1):42-51doi: 10.1097/00008877-199402000-00005.
López-Rubalcava, C., & Fernández-Guasti, A. (1994). Noradrenaline-serotonin interactions in the anxiolytic effects of 5-HT(1A) agonists. Behavioural pharmacology, 5(1), 42-51. https://doi.org/10.1097/00008877-199402000-00005
López-Rubalcava, C., and Fernández-Guasti, A.. "Noradrenaline-serotonin interactions in the anxiolytic effects of 5-HT(1A) agonists." Behavioural pharmacology vol. 5,1 (1994): 42-51. doi: https://doi.org/10.1097/00008877-199402000-00005
López-Rubalcava C, Fernández-Guasti A. Noradrenaline-serotonin interactions in the anxiolytic effects of 5-HT(1A) agonists. Behav Pharmacol. 1994 Feb;5(1):42-51. doi: 10.1097/00008877-199402000-00005. PMID: 11224250.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 191 entries